Drug intelligence / Profile preview

metronidazole + ciprofloxacin + minocycline

Development stage
Phase 4
Lead developer
Hoshino et al.
Modality
Small Molecules
Administration
Topical
01

Overview

A combination of three antibiotics—metronidazole (a nitroimidazole compound), ciprofloxacin (a synthetic fluoroquinolone), and minocycline (a semisynthetic tetracycline derivative)—used primarily as an intracanal medicament in endodontics. This mixture is known as Triple Antibiotic Paste (TAP) or 3-mix paste. It was developed to address the polymicrobial nature of root canal infections that cannot be effectively treated by a single antibiotic. The combination provides broad-spectrum antibacterial activity against gram-positive bacteria, gram-negative bacteria, and anaerobes. Metronidazole targets anaerobic bacteria and protozoa; ciprofloxacin is bactericidal with high activity against gram-negative organisms; minocycline is bacteriostatic with a broad spectrum including both gram-positive and some gram-negative organisms. TAP is used for disinfection in regenerative endodontic procedures such as pulp revascularization and lesion sterilization/tissue repair therapy[1][2][3][4][6].

Brand names
Neosporin
Other names
triple antibiotic pasteTAP3-mix paste
02

Targets

Bacterial RibosomeNeuraminidaseDNA gyraseTopo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on metronidazole + ciprofloxacin + minocycline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on metronidazole + ciprofloxacin + minocycline.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call